Lannett Company, the U.S. subsidiary of Aurobindo Pharma, has launched a generic version of the inhalation product Advair Diskus in the United States [1, 2].
The move allows Aurobindo Pharma to enter the specialized U.S. inhalation segment, a move that investors reacted to positively this week.
The company is targeting a potential revenue opportunity estimated between $60 million and $70 million [2]. This launch places the firm in a competitive landscape where only three or four companies are currently competing in the Advair generic market [2].
The broader U.S. inhalation market for the Advair generic is valued between $650 million and $700 million [2]. By securing a foothold in this segment, Aurobindo Pharma aims to diversify its product portfolio beyond standard oral medications.
Market reaction to the announcement was immediate. Aurobindo Pharma shares rose over 3% on the day of the launch [1]. This gain contributes to a stronger overall performance for the company this year, with the stock up 41% year-to-date [1].
Lannett Company will manage the distribution and commercialization of the product within the U.S. market [1, 2]. The introduction of generic alternatives typically increases patient access to critical respiratory medications by lowering costs compared to brand-name versions.
“Aurobindo Pharma shares rose over 3% on the day of the launch”
The entry of Aurobindo Pharma into the inhalation market signals a strategic shift toward high-barrier generic products. Because inhalation technology is more complex to manufacture than traditional pills, the limited number of competitors—only three or four—suggests a higher potential for profit margins and market stability compared to more saturated generic segments.
